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ABSTRACT
Introduction Pulmonary rehabilitation (PR), an exercise 
and education programme for people with chronic lung 
disease, aims to improve exercise capacity, breathlessness 
and quality of life. Most evidence to support PR is from 
trials that use specialist exercise equipment, for example, 
treadmills (PR- gym). However, a significant proportion of 
programmes do not have access to specialist equipment 
with training completed with minimal exercise equipment 
(PR- min). There is a paucity of robust literature examining 
the efficacy of supervised, centre- based PR- min. We aim 
to determine whether an 8- week supervised, centre- based 
PR- min programme is non- inferior to a standard 8- week 
supervised, centre- based PR- gym programme in terms of 
exercise capacity and health outcomes for patients with 
chronic lung disease.
Methods and analysis Parallel, two- group, assessor- 
blinded and statistician- blinded, non- inferiority randomised 
trial. 436 participants will be randomised using 
minimisation at the individual level with a 1:1 allocation to 
PR- min (intervention) or PR- gym (control). Assessment will 
take place pre- PR (visit 1), post- PR (visit 2) and 12 months 
following visit 1 (visit 3). Exercise capacity (incremental 
shuttle walk test), dyspnoea (Chronic Respiratory 
Questionnaire (CRQ)- Dyspnoea), health- related quality 
of life (CRQ), frailty (Short Physical Performance Battery), 
muscle strength (isometric quadriceps maximum voluntary 
contraction), patient satisfaction (Global Rating of Change 
Questionnaire), health economic as well as safety and 
trial process data will be measured. The primary outcome 
is change in exercise capacity between visit 1 and visit 
2. Two sample t- tests on an intention to treat basis will 
be used to estimate the difference in mean primary and 
secondary outcomes between patients randomised to PR- 
gym and PR- min.
Ethics and dissemination London- Camden and Kings 
Cross Research Ethics Committee and Health Research 
Authority have approved the study (18/LO/0315). Results 
will be submitted for publication in peer- reviewed journals, 
presented at international conferences, disseminated 
through social media, patient and public routes and 
directly shared with stakeholders.
Trial registration number ISRCTN16196765.
INTRODUCTION
Background and rationale
Pulmonary rehabilitation (PR), an evidence- 
based exercise and education programme, is 
widely accepted as a cornerstone of manage-
ment for people with chronic obstructive 
pulmonary disease (COPD) and other 
chronic respiratory disorders.1 The most 
recent Cochrane review, comprising 65 
randomised controlled trials (n=3822), stated 
that no further trials comparing PR and stan-
dard care in patient with COPD were neces-
sary as the evidence supporting the benefits 
of PR on exercise capacity and health- related 
quality of life were conclusive.2
The majority of evidence to support PR 
has come from trials conducted in hospital 
or rehabilitation centres that use specialist 
exercise equipment such as treadmills, cycle 
ergometers and weights machines (PR- gym).2 
However, in clinical practice, supply does 
Strengths and limitations of this study
 ► This is a parallel, two- group, assessor- blinded and 
statistician- blinded, non- inferiority randomised tri-
al to assess the primary and secondary outcome 
measures.
 ► The pulmonary rehabilitation intervention is delivered 
according to national guidelines: British Thoracic 
Society Guideline on Pulmonary Rehabilitation in 
Adults.
 ► The study includes a 12- month follow- up period to 
evaluate the long- term effect of the intervention.
 ► The study includes a health- economic anal-
ysis which aims to understand relative cost- 
effectiveness which may have implications for NHS 
commissioning.
 ► This is a single- centre study based in northwest 
London and findings may not be applicable to other 
populations in different locations.
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not meet demand, and routine access to specialist equip-
ment may not be feasible.3 For example, the 2015 Royal 
College of Physicians National Audit identified that PR 
services in England and Wales received 68 000 referrals 
in 2014 out of an estimated 446 000 eligible patients with 
COPD.3 Furthermore, 82% of patients enrolled in a PR 
programme in England and Wales in 2017 were hosted in 
a community site such as a community centre or church 
hall, of which 61% most likely did not exercise using 
specialist equipment.4 Accordingly, exercise training at 
these sites, although supervised by PR professionals, was 
completed with minimal equipment (PR- min), typically 
using portable equipment such as free weights, elastic 
resistance bands (eg, Theraband), walking courses and 
bodyweight resistance exercises.3
Apart from improving accessibility, it has been argued 
that PR- min may have other advantages over PR- gym. 
Exercise- training using minimal equipment may better 
reflect activities of daily- living than training using 
specialist equipment and therefore be easier to repli-
cate and maintain at home following discharge from PR. 
However, it may be more difficult to prescribe and prog-
ress exercise, particularly resistance exercise, without the 
use of specialist equipment.
A systematic review, conducted by Alison and 
colleagues, identified eight randomised controlled trials 
that compared outcomes following exercise interven-
tions completed with minimal equipment to usual care 
without an exercise intervention in patients with COPD.5 
The results were conflicting for exercise outcomes. In 
four studies (n=182) where the 6 min walk test was used 
as the primary outcome measure of exercise capacity, the 
pooled effect showed a mean (95% CI) between- group 
difference of 40 (13 to 67) m favouring the intervention 
group.5 Conversely, in the other four studies (n=389) that 
used the incremental shuttle walk test (ISW), there was 
no significant mean (95% CI) between- group difference: 
21 (−9 to 51) m.5 For health- related quality of life, results 
were similarly conflicting.5 Whereas in the four studies 
that used the St. George’s Respiratory Questionnaire 
there was a sizeable difference between the intervention 
and control groups (mean (95% CI): −7 (−12 to −3)), the 
mean between- group difference of the Chronic Respi-
ratory Questionnaire dyspnoea (CRQ- D) and fatigue 
domains (CRQ- F) did not reach the minimum clinically 
important difference (MCID) in three other studies.5 
Only one of the eight studies measured muscle strength 
but results were reported descriptively with no statistical 
testing.5 Furthermore, only one of the eight studies would 
fulfil the British Thoracic Society (BTS) guidelines defini-
tion of PR,1 with seven studies not offering any education 
component.5
To our knowledge, no trial has compared supervised 
centre- based PR using minimal and specialist equip-
ment. A previous National Institute for Health Research 
Health Technology Assessment- funded randomised 2×2 
trial compared PR undertaken in community venues with 
PR undertaken in a hospital venue, in 240 patients with 
COPD.6 Participants were block randomised (hospital 
n=129; community n=111). Both groups received two 
times a week PR for 6 weeks with the exercise training 
protocol identical in both venues. Importantly, neither 
community nor hospital sites had access to specialist exer-
cise equipment. Patients in both groups improved their 
walking distance, exceeding the MCID of the endurance 
shuttle walk test, and there were similar improvements 
in health- related quality of life.6 Although the results 
support the conclusion that the efficacy of PR- min is 
not influenced by hospital or community locations, this 
study did not address whether PR- min is non- inferior to 
‘gold standard’ PR- gymOur group recently conducted an 
observational cohort study to compare if an 8 week super-
vised, centre- based PR- min programme was non- inferior 
to PR- gym in terms of core PR outcomes in patients with 
COPD.7 Using propensity score matching, 318 consecu-
tive patients undergoing PR- min were compared 1:1 with 
a control group of 318 patients who underwent PR- gym. 
Similar short- term improvements in exercise capacity 
and health- related quality of life were observed in both 
groups (mean (95% CI) difference: ISW: 3 (−16 to 9) 
m; CRQ- total: 0.9 (−2.7 to 4.5)). Furthermore, the 95% 
CI between- group differences for these outcomes did 
not cross the predefined non- inferiority margins. These 
data suggest that PR- min is non- inferior to PR- gym with 
regard to short- term improvements in exercise capacity 
and health- related quality of life. However, this study was 
not randomised, only included short- term outcomes and 
no attempt was made to estimate costs. A randomised 
controlled trial with more varied outcome measures 
(such as lower limb muscle strength), longer follow- up 
and a health economic analysis, is required to confirm 
these findings.
The aims of the research are to determine whether 
an 8- week outpatient supervised PR- min programme 
is non- inferior to a standard 8- week outpatient super-
vised PR- gym programme in terms of health benefits for 
patients with chronic respiratory disease.
The primary objective is to determine whether 
PR- min is non- inferior to PR- gym regarding change in 
exercise capacity measured using ISW8 distance from 
baseline (visit 1) to post- PR assessment at 8 weeks (visit 
2).
The secondary objectives are to: (1) determine whether 
PR- min is non- inferior to PR- gym regarding changes 
breathlessness (CRQ- D), health- related quality of life 
(CRQ) and quadriceps strength (isometric quadriceps 
maximum voluntary contraction) from baseline (visit 
1) to post- PR assessment at 8 weeks (visit 2) and from 
baseline (visit 1) to 12 months after the baseline assess-
ment (visit 3); (2) evaluate the trial process by recording 
the participant recruitment and retention, participant 
uptake of PR, PR attendance, PR completion, reasons for 
PR non- completion and participant satisfaction in each 
arm of the study, at the appropriate stage of the trial; (3) 
estimate the cost and cost- effectiveness during the trial 
period.




This study has been approved by the Health Research 
Authority and London Camden and Kings Cross Research 
Ethics Committee (reference 18/LO/0315). All partici-
pants will provide written informed consent.
Study design
This is a parallel, two- group, assessor- blinded and 
statistician- blinded, non- inferiority, randomised trial. 
Participants will be randomised at the individual level 
with a 1:1 allocation to either PR- min or PR- gym. Both 
interventions will comprise two supervised sessions per 
week for 8 weeks delivered by the same team. Outcome 
measures will be recorded at baseline assessment for 
PR (visit 1), following PR at 8 weeks (visit 2) and at 12 
months after visit 1 (visit 3). The study schema is outlined 
in figure 1.
Study population
Potential participants will be people referred to Harefield 
Pulmonary Rehabilitation Unit, Royal Brompton and 
Harefield Clinical Group, UK who meet the following 
inclusion criteria (1) adults >18 years of age; (2) physi-
cian diagnosis of stable chronic respiratory disease, 
typically COPD, interstitial lung disease, bronchiectasis, 
chronic asthma or chest wall disease; (3) referred for PR 
in line with BTS guidelines (ie, ambulatory—can walk ≥5 
Figure 1 Study schema. CRQ- D, Chronic Respiratory Questionnaire- Dyspnoea; CRQ- T, Chronic Respiratory Questionnaire- 
Total Score; CVS, Cardiovascular Disease; ISW, Incremental Shuttle Walk Test; KCTU, King’s Clinical Trials Unit; MRC, Medical 
Research Council; PR, Pulmonary Rehabilitation; QMVC, Quadriceps Maximum Voluntary Contraction.
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m, functional impairment related to breathlessness, typi-
cally Medical Research Council dyspnoea score ≥2); (4) 
able to communicate verbally and respond to questions in 
written English. Potential participants will be excluded if 
they have (1) any contraindication to moderate intensity 
physical exercise, for example, unstable cardiovascular 
disease; (2) progressive cancer or neurological disorder 
with an expected life expectancy less than 12 months; (3) 
completed PR within previous 12 months and/or (4) are 
unable to provide informed consent.
Consent
Informed consent will be obtained by the nominated 
researchers as recorded in the Sponsor’s Delegation of 
Responsibilities Log. All individuals taking informed 
consent will have received consent training. All partic-
ipants will provide written consent. Consent to enter 
this study will be obtained after a full account has been 
provided of its nature, purpose, risks, burdens and poten-
tial benefits, and the patient has had the opportunity to 
deliberate. The patient will be allowed to specify the time 
they wish to spend deliberating, usually up to 24 hours. 
The Investigator or designee will explain that the patients 
are under no obligation to enter the study and that they 
can withdraw at any time during the study, without having 
to give a reason. At each visit, the participant’s willingness 
to continue in the study will be ascertained and docu-
mented in the research notes. A copy of the consent form 
is in the online supplemental file.
Screening and recruitment
Following clinical referral, but prior to pre- PR assessment, 
potential participants will be screened by a member of the 
PR team for eligibility to the study. The potential partic-
ipant will be approached by telephone and provided 
with a participant information sheet. A member of the 
research team will obtain informed consent following the 
pre- PR assessment.
Randomisation, allocation and blinding procedures
Consenting participants will be randomised at the indi-
vidual level with a 1:1 allocation, using an independent 
web- based system provided by the United Kingdom Clin-
ical Research Collaboration registered King’s Clinical 
Trials Unit (KCTU), to receive either ‘usual care’ (PR- 
gym) or intervention (PR- min).
Randomisation by minimisation will ensure that partic-
ipant characteristics are balanced between the groups 
with respect to previous completion of PR (yes/no), 
multiple deprivation index (most deprived quintile of 
index: yes/no9 and frailty status (Short Physical Perfor-
mance Battery score <10/≥10.10 A proportion of patients 
will be entered initially using simple randomisation in 
order to create a level of initial imbalance and the mini-
misation algorithm will maintain a level of randomness in 
order to preserve prerandomisation allocation conceal-
ment. Once randomised, the system will automatically 
generate a full audit trail of the process and send email to 
relevant investigators in a blinded or unblinded format, 
depending on their role. For each arm, participants will 
be provided with a choice of three sites in northwest 
London to undertake PR.
Owing to the nature of the interventions, participants 
and providers of the intervention will not be blinded. 
However postrehabilitation assessments will be performed 
by a researcher blinded to group allocation and not 
involved in the delivery of either intervention arm. The 
trial statistician will also be blinded to group allocation.
Study intervention
PR-gym (control group)
The control intervention will be current gold- standard 
clinical practice. PR- gym will comprise an 8- week outpa-
tient exercise and multidisciplinary self- management 
education programme, with two supervised and at least 
one additional home session each week, and delivered 
according to the BTS Quality Standards for PR.11 Super-
vising staff will comprise specialist respiratory therapists 
with a minimum of 2 years’ experience in PR. Available 
equipment will include treadmills, cycle ergometers, 
cross- trainers, specialist lower limb resistance equipment 
(eg, leg press, knee extension). Each supervised session 
will consist of 1 hour of exercise (at least 30 min aerobic 
exercise) and 45 min of education.
Initial walking speed prescription on the treadmill will 
be 80% of predicted peak oxygen consumption based 
on baseline ISW performance,8 while initial endurance 
cycling will be initially set to achieve level 3 to 4 on the 
Borg CR- 10 Dyspnoea Scale with the aim of patients 
completing 10 min of continuous training. Lower limb 
resistance training will comprise two sets of 10 leg press 
repetitions on specialist resistance equipment performed 
with an initial training load of 60% one- repetition 
maximum. Similarly, two sets of 10 bilateral knee exten-
sion repetitions will be performed on specialist resistance 
equipment at an initial training load of 60% one- repetition 
maximum. This will be supplemented with sit- to- stand 
sets, plus knee lifts/extension and hip abduction with 
appropriate ankle weights up to 10 kg. Upper limb resis-
tance training will comprise biceps curls, shoulder press 
and upright row with free weights or Therabands (red to 
black). Exercise training will be individualised and regu-
larly progressed (duration and/or intensity) according 
to standard operating procedures, with targets reviewed 
at each session. Education will be delivered by a multi-
disciplinary team with topics chosen to develop patients’ 
understanding and holistic management of their disease. 
Further detail on the education programme and safety 
measures for the rehabilitation programme are provided 
in the online supplemental file.
PR-min (Intervention group)
PR- min will also comprise an 8- week outpatient exer-
cise and multidisciplinary self- management education 
programme, with two supervised and at least one addi-
tional home session each week, and delivered according 
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to the BTS Quality Standards for PR.11 As for PR- gym, 
supervising staff will comprise specialist respiratory thera-
pists with at least 2 years’ experience of in PR. There will 
be no access to treadmills, cycle ergometers or specialist 
resistance equipment. Available exercise equipment 
will include walking circuit, portable steppers, portable 
pedals, hand and ankle weights (up to 5 kg), and Thera-
bands (red to black). Each supervised session will consist 
of 1 hour of exercise (at least 30 min aerobic exercise) 
and 45 min of education.
Initial walking speed prescription will be 80% of 
predicted peak oxygen consumption based on baseline 
ISW performance. Participants will be provided with a 
stopwatch and given time targets to complete a walking 
course of known distance. Although the resistance of the 
portable steppers and pedals can be manually adjusted, 
this cannot be objectively quantified. Initial prescrip-
tion will be set at ‘level 1’ but individually adjusted to 
find an intensity where patients can complete 10 min of 
continuous training with a target modified Borg breath-
less score of 3–4 and a Borg rating of Perceived Exer-
tion of 13–15 (on a scale of 6–20). Resistance training 
will include functional activities such as sit- to- stand and 
step- ups as well as Theraband based exercises such as 
sitting knee extension, leg press and hip flexion as well 
as standing hip extension, squats, chest press and lateral 
raise. Progression will be through the use of hand/ankle 
weights and increasing resistant Therabands (from red 
to black). Exercise training will be individualised and 
regularly progressed (either in duration or intensity) 
with targets reviewed at each supervised session. Educa-
tion will be delivered by a multidisciplinary team as per 
PR- gym (online supplemental file). Information on safety 
measures for the rehabilitation programme is provided in 
the online supplemental file.
Study outcome measures
A list of the scheduled outcomes is outlined in table 1 and 
described in detail in the online supplemental file.
Sample size calculation
Previous audits of Harefield PR Unit have shown that in 
participants undergoing PR- gym achieve a mean (SD) 
change in ISW of 58 (67) m. The null hypothesis is that 
PR- min is inferior to the standard treatment PR- gym. 
The alternative hypothesis is that PR- min is not inferior 
to PR- gym. The non- inferiority margin will be defined as 
half the known MCID using the fixed- margin method with 
a preserved effect of 50% as recommended by previous 
guidance, including from the United States Food and 
Drug Administration.12 13 The MCID of the ISW is 47.5 
m,14 and therefore 24 m will be considered the non- 
inferiority margin. If there is truly no difference between 
PR- min and PR- gym, then a minimum of 246 patients 
(123 in each group) is required to be 80% sure that the 
lower limit of a one- sided 97.5% CI (or equivalently a 
95% two- sided CI) will be above the non- inferiority limit 
of −24 m. Based on audit data, we anticipate 32% dropout 
from PR (12% from assessment to starting PR and 20% 
from starting PR to completing PR). Taking into account 
dropout, the original minimum sample size required 
for analysis was 362 patients (181 patients per group). 
However, owing to the impact of the COVID- 19 pandemic 
on the study (described in the Amendment section), the 
study sample size was increased by a further 74–436 (218 
patients per group).
Statistical analysis
For baseline data, continuous and categorical variables 
will be summarised with descriptive statistics. No signifi-
cance testing will be carried out. The outcome measures 
will be described by trial arm and at visits 1, 2 and 3 using 
descriptive statistics.
The main statistical analyses will estimate the differ-
ence in mean primary and secondary outcomes between 
patients randomised to PR- gym and PR- min by intention 
to treat principle from visit 1 to visit 2 (8 weeks following 
visit 1) and visit 1 to visit 3 (12 months following visit 1). 
Group difference estimates and associated one- sided 
97.5% CI will be reported. The group differences will be 
compared using one- sided two independent sample t- test 
Table 1 Study outcome measures
Visit 1 Visit 2 Visit 3
Primary outcome measure: exercise capacity (incremental shuttle walk test) X X X
Spirometry X   X
Frailty (Short Physical Performance Battery) X X X
Dyspnoea (Chronic Respiratory Questionnaire- Dyspnoea domain) X X X
Health- related quality of life (Chronic Respiratory Questionnaire) X X X
Muscle strength (Isometric Quadriceps Maximum Voluntary Contraction) X X X
Patient satisfaction (Global Rating of Change Questionnaire)   X   
Health- economic evaluation (Modified Client Service Receipt Inventory Scale, 
Euro- Qol- 5 Dimensions- 5 Levels, NHS Digital—after visit 3 only)
X X X
Safety and trial process evaluation X X X
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or non- parametric equivalent. The significance level is set 
at one- sided significance level of 0.025.
Regarding missing data, the number of baseline vari-
ables with complete data will be reported and the primary 
and secondary outcomes will be analysed as per the 
recommendations of White et al.15 Missing postrando-
misation assessments will be dealt with using an appro-
priate method of imputation, depending on the missing 
mechanism.
Adherence is defined as the number of supervised 
sessions the participant attends irrespective of the 
assigned intervention (maximum 16). This will be 
recorded in both intervention arms. As a dichotomous 
indicator with eight as the cut- off. The following vari-
ables will be recorded in a 3×2 table according to allo-
cated intervention: (1) compliers always receive the 
allocated treatment; (2) complete defiers do the oppo-
site of the allocated treatment, that is, attend no sessions 
in allocated treatment; (3) partial defiers are all others 
not falling in the above groups. Dropout cause will be 
recorded using the MORECARE classification of reason 
for attrition.16
In addition to the primary intention- to- treat analysis, 
the effect of actually receiving treatment as defined in 
the protocol will also be estimated. If non- compliance 
rate with PR sessions is >10%, a Complier- Average 
Causal- Effect (CACE) will be estimated.17 The following 
sensitivity analyses are planned: (1) per protocol; (2) 
including only those in the upper quartile for baseline 
ISW; (3) complete case; (4) complier Average Causal 
Effects (CACE) analysis17 and (5) primary diagnosis 
of COPD; (6) a generalised estimating equation- based 
analysis to estimate the treatment effects, adjusting for 
imbalance if the group difference in the percentage of 
smokers, participants age <70 years, or females is greater 
than 20% at baseline.
Data collection, management and monitoring
A web based electronic data capture (EDC) system has 
been designed using the InferMed Macro 4 system and 
will be maintained by KCTU for the duration of the 
project. Source data will be entered by recruiting site staff, 
typically within 1 week of data collection by authorised 
staff onto the EDC. A full audit trial of data entry and any 
subsequent changes to entered data will be automatically 
date and time stamped, alongside information about the 
user making the entry/changes within the system.
The primary investigator (WM) will take overall respon-
sibility for the conduct of MISTER. The trial co- ordinator 
(CMN) will supervise the day- to- day operation of the 
project and is responsible for ensuring that Good Clinical 
Practice guidelines are followed. An unblinded member 
of the MISTER research team (JAW) will monitor the 
data and review a random sample of 10% of completed 
case report forms against clinical records. Monitoring will 
ensure protocol compliance, proper study management 
and timely completion of study procedures.
Monitoring and auditing
A Data Monitoring and Ethics Committee has been 
appointed. The members of this committee are not 
members of the applicants’ or sponsors’ institution and 
include an academic Consultant Respiratory Physician 
and an independent statistician.
The requirement for study monitoring or audit will be 
based on the Sponsor’s Research Office risk assessment 
procedure and applicable standard operating proce-
dures. It is the responsibility of the Research Office to 
determine the monitoring risk assessment and explain 
the rationale to the study research team.
Patient and public involvement (PPI)
The concept of the research project arose directly from 
PPI, and the development of this project has included PPI 
throughout each stage. We have a named PPI coapplicant 
who will continue to be closely involved in the design and 
management of the research through membership of the 
Trial Steering Group that will meet at the beginning of 
the research period, and then every 6 months throughout 
the data collection/analysis and dissemination period. 
This PPI member will be joined by a second representa-
tive and will meet the project manager at regular intervals 
throughout the study. The PPI group will provide input 
into written material for patients, how results data are 
presented, particularly to lay audiences and will have a 
role in dissemination of research findings.
Safety monitoring
A serious adverse event (SAE) is defined as an untoward 
occurrence that (a) results in death; (b) is life- threatening; 
(c) requires hospitalisation or prolongation of existing 
hospitalisation; (d) results in persistent or significant 
disability or incapacity or (e) is otherwise considered 
medically significant by the investigator.
The Investigator and research team are responsible for 
reporting events to the Research Office immediately and/
or within 24 hours of becoming aware of the event. An 
SAE occurring to a research participant will be reported 
to the Research Ethics Committee that gave a favourable 
opinion of the study.
Amendment
Owing to the COVID- 19 pandemic the study was 
suspended for 13 months between February 2020 and 
2021 and, at the date of study suspension, there were 74 
recruited and randomised participants waiting to start 
PR but were unable to receive either intervention due to 
the pandemic. Accordingly, a substantial amendment to 
increase the sample size from 362 to 436 and extend the 
recruitment and follow- up periods by 1 year to 31 March 
2022 and 2023, respectively, was submitted to the funders 
(National Institute for Health Research), the Health 
Research Authority and research ethics committee on 5 
February 2021. These amendments were approved on 24 
February 2021.
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Should further substantial amendments be made, a 
notice of amendment will be submitted to the Health 
Research Authority for consideration.
Study timelines
Participant recruitment started on 15 October 2018 and 
is expected to end on 31 March 2022. Visit 2 assessments 
started approximately 8 weeks after visit 1 and visit 3 
assessments 12 months after visit 1. The final visit 2 assess-
ment is expected to take place on 31 May 2023. The end 
date for the study, representing the final visit 3 will be 31 
March 2023.
DISSEMINATION
We will use a broad strategy to maximise dissemination 
of our findings: (1) sharing of scientific findings via 
open- access publication in high impact journals and 
presentation at international meetings; (2) plain English 
summaries of findings for public bodies and web- sites 
(eg, NIHR, CLARHC, British Lung Foundation,  patient. 
co. uk) to communicate evidence through a user- friendly 
interface; (3) online pages about the project on websites 
of contributing organisations (Guy’s and St Thomas’ 
NHS Foundation Trust, Cicely Saunders Institute, King’s 
College London); (4) social media (eg, Twitter); (5) 
public engagement via talks with service user groups 
and open public events, so patients and their caregivers 
can learn about the research; (6) direct sharing of find-
ings with public bodies (eg, National Horizon Scanning 
Research and Intelligence Centre) and policy makers to 
whom the applicants have direct access (eg, BTS Pulmo-
nary Rehabilitation Advisory Group, European Respi-
ratory Society, American Thoracic Society, Society for 
Research in Rehabilitation) to facilitate uptake of find-
ings into research strategy and policy; (7) education of 
commissioners to influence future NHS service delivery.
DISCUSSION
PR is a core strategy in the management for COPD and 
other chronic respiratory disorders.1 The majority of 
evidence to support PR has come from trials conducted 
in locations that use specialist exercise equipment.2 Data 
from a national audit indicate that many PR programmes 
in England and Wales do not have access to specialist 
exercise equipment with exercise training completed 
using simple equipment.3 There is a paucity of robust 
literature examining the efficacy of PR- min and to our 
knowledge, there have been no trials comparing super-
vised centre- based PR- min and PR- gym. One observa-
tional study demonstrated that PR- min is non- inferior to 
PR- gym in terms of exercise capacity and health- related 
quality of life but indicated that further investigation 
using a randomised controlled trial is required.7 There-
fore, this study aims to bridge the gap in knowledge by 
identifying whether PR- min is non- inferior to PR- gym 
regarding change in core PR outcome measures. This is 
an important and current health service question given 
the increasing disparity between supply and demand of 
PR that has implications for the delivery and future devel-
opment of this programme at national and international 
levels.
The strengths of this study include the design: a 
parallel, two- group, assessor- blinded and statistician- 
blinded, non- inferiority randomised trial which is the 
appropriate design to assess the primary and secondary 
outcome measures. The intervention, PR, is delivered 
according to national guidelines and the population of 
interest is people with chronic respiratory disease, both of 
which mean the results will be generalisable. In addition, 
study involves a 12- month follow- up period (from visit 1) 
to evaluate the long- term effect of the intervention and a 
health- economic analysis which aims to understand the 
potential cost- effectiveness of the trial which may have 
implications for the NHS and Clinical Commissioning 
Groups. A limitation of the study is that it is a single- 
centre study based in northwest London which may mean 
that the findings may not be generalisable to other popu-
lations in different locations.
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